睿知中国疾病研究地图
候选清单0

即将招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ

ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07912957,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. HER2 intermediate-to-high expression by immunohistochemistry (IHC) 2+ or 3+. 6. No prior antitumor therapy for esophageal or gastric adenocarcinoma. 7. Availability of tumor tissue (primary tumor or metastatic lymph node) for pathological testing, including paraffin block, paraffin-embedded sections, or fresh tissue sections; archival tissue is preferred. If unavailable, a new baseline biopsy is required.

    入选标准第 5 条

  3. History of another primary malignancy, except for: basal cell carcinoma of the skin, superficial bladder cancer (Ta, non-invasive), squamous cell carcinoma of the skin, or carcinoma in situ of the cervix; or malignancies that have received curative treatment and remained recurrence-free for ≥5 years.

    排除标准第 3 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 7 days before study drug administration.

    入选标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07912957,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary signed informed consent and willingness to comply with protocol requirements.
  2. Age ≥18 years at the time of informed consent signing; both sexes eligible.
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 7 days before study drug administration.
  4. Resectable locally advanced esophageal or gastric adenocarcinoma, as determined by the investigator, staged as cT1b-2 N+ M0 or cT3-4 Nany M0 (AJCC 8th edition).
  5. HER2 intermediate-to-high expression by immunohistochemistry (IHC) 2+ or 3+. 6. No prior antitumor therapy for esophageal or gastric adenocarcinoma. 7. Availability of tumor tissue (primary tumor or metastatic lymph node) for pathological testing, including paraffin block, paraffin-embedded sections, or fresh tissue sections; archival tissue is preferred. If unavailable, a new baseline biopsy is required.
  6. No severe cardiac dysfunction; left ventricular ejection fraction (left ventricular ejection fraction, LVEF) ≥55% within 28 days before study drug administration.
  7. Adequate organ function within 7 days before study drug administration, defined as:
  8. Hematologic function:
  9. Hepatic function:
  10. Renal function:
  11. Coagulation function:
  12. Urinalysis:

排除标准:Exclusion Criteria:

  1. Pathological diagnosis of HER2-negative esophageal or gastric adenocarcinoma, defined as HER2 IHC 0 or 1+.
  2. Presence of contraindications to esophageal or gastric surgical resection.
  3. History of another primary malignancy, except for: basal cell carcinoma of the skin, superficial bladder cancer (Ta, non-invasive), squamous cell carcinoma of the skin, or carcinoma in situ of the cervix; or malignancies that have received curative treatment and remained recurrence-free for ≥5 years.
  4. Presence of non-regional lymph node or distant organ metastasis. For suspected peritoneal carcinomatosis or ascites on imaging, histological or cytological confirmation via laparoscopy or other procedures is required.
  5. Significant clinically meaningful bleeding or definite bleeding tendency within 1 month before informed consent, such as gastrointestinal bleeding or fecal occult blood ≥2+ (positive); or endoscopically, radiologically, or highly suspected esophageal fistula or gastric perforation.
  6. Any serious or uncontrolled systemic disease at the discretion of the investigator, including uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), uncontrolled diabetes mellitus, or signs of active bleeding.
  7. Serious cardiovascular or cerebrovascular disease, including but not limited to: NYHA class II or greater heart failure; myocardial infarction or cerebrovascular accident (cerebral ischemia, symptomatic cerebral infarction, etc.) within 3 months before the first dose; grade ≥2 persistent arrhythmia (per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ); atrial fibrillation of any grade; unstable arrhythmia or unstable angina within 1 month before the first dose in patients with coronary artery disease; congestive heart failure not meeting the above criteria; or symptomatic superior vena cava syndrome.
  8. Evidence of active infection, including hepatitis B (HBsAg positive with HBV DNA ≥2000 IU/mL, after excluding drug-induced or other causes of hepatitis), hepatitis C (anti-HCV antibody positive with HCV RNA above the lower limit of detection), or human immunodeficiency virus (HIV) infection; or uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infection unless treated and resolved before study drug administration.
  9. History of hypersensitivity to any component of the study drugs, or history of grade ≥3 hypersensitivity to macromolecular protein preparations or monoclonal antibodies.
  10. History of primary immunodeficiency or active autoimmune disease; or current use of immunosuppressants or systemic corticosteroids (≥10 mg/day prednisone or equivalent) that continued within 2 weeks before enrollment.
  11. History of interstitial pneumonia, radiation pneumonitis, severe chronic obstructive pulmonary disease, severe pulmonary dysfunction, or symptomatic bronchospasm.
  12. Breastfeeding women unwilling to use adequate contraception during the study and for 6 months after the last dose of study drug.
  13. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment in this clinical trial.

引自 ClinicalTrials.gov, NCT07912957, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07912957,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07912957